1: Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R,
Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner
L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS,
Engelman JA, Stuart DD, Cooke VG, Caponigro G. LXH254, a Potent and Selective
ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Clin Cancer Res. 2021 Apr 1;27(7):2061-2073. doi: 10.1158/1078-0432.CCR-20-2563.
Epub 2020 Dec 22. PMID: 33355204.
2: Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der
Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F,
Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer
R. First-in-human study of naporafenib (LXH254) with or without spartalizumab in
adult patients with advanced solid tumors harboring MAPK signaling pathway
alterations. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458.
Epub 2023 Nov 21. PMID: 38039779; PMCID: PMC11380116.
3: Li R, Ren M, Lu W, Yuan Y, Li J, Zhong W. A validated LC-MS/MS method for the
determination of RAF inhibitor LXH254: Application to pharmacokinetic study in
rat. Biomed Chromatogr. 2021 Feb;35(2):e4968. doi: 10.1002/bmc.4968. Epub 2020
Sep 16. PMID: 32881002.
4: de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D,
Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M,
Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A,
Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M,
Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With
Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a
Phase Ib, Open-Label Study. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi:
10.1200/JCO.22.02018. Epub 2023 Mar 22. PMID: 36947734.
5: Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck
MJ. Structure and RAF family kinase isoform selectivity of type II RAF
inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May;299(5):104634.
doi: 10.1016/j.jbc.2023.104634. Epub 2023 Mar 22. PMID: 36963492; PMCID:
PMC10149214.
6: Planchard D, Wolf J, Solomon B, Sebastian M, Wermke M, Heist RS, Sun JM, Min
Kim T, Reguart N, Sanmamed MF, Felip E, Garrido P, Santoro A, Bootle D,
Couillebault XM, Gaur A, Mueller C, Poggio T, Yang J, Moschetta M, Dooms C. A
phase Ib study of the combination of naporafenib with rineterkib or trametinib
in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell
lung cancer. Lung Cancer. 2024 Nov;197:107964. doi:
10.1016/j.lungcan.2024.107964. Epub 2024 Sep 26. PMID: 39383771.
7: Christen D, Lauinger M, Brunner M, Dengjel J, Brummer T. The mTOR pathway
controls phosphorylation of BRAF at T401. Cell Commun Signal. 2024 Sep
2;22(1):428. doi: 10.1186/s12964-024-01808-2. PMID: 39223665; PMCID:
PMC11370054.
8: Park S, Kim TM, Cho SY, Kim S, Oh Y, Kim M, Keam B, Kim DW, Heo DS. Combined
blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-
small cell lung cancer cells. Cancer Lett. 2020 Dec 28;495:135-144. doi:
10.1016/j.canlet.2020.09.018. Epub 2020 Sep 23. PMID: 32979462.
9: Vasta JD, Michaud A, Zimprich CA, Beck MT, Swiatnicki MR, Zegzouti H, Thomas
MR, Wilkinson J, Crapster JA, Robers MB. Protomer selectivity of type II RAF
inhibitors within the RAS/RAF complex. Cell Chem Biol. 2023 Nov
16;30(11):1354-1365.e6. doi: 10.1016/j.chembiol.2023.07.019. Epub 2023 Aug 28.
PMID: 37643616.
10: Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M, Knox JJ,
Radulovich N, Tamblyn L, Xie IY, Horak P, Forschner A, Bitzer M, Wittel UA,
Boerries M, Ball CR, Heining C, Glimm H, Fröhlich M, Hübschmann D, Gallinger S,
Fritsch R, Fröhling S, O'Kane GM, Dengjel J, Brummer T. BRAFΔβ3-αC
in-frame deletion mutants differ in their dimerization propensity, HSP90
dependence, and druggability. Sci Adv. 2023 Sep;9(35):eade7486. doi:
10.1126/sciadv.ade7486. Epub 2023 Sep 1. PMID: 37656784; PMCID: PMC11804575.
